Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1282 participants.

Also called NCT01606007

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,282 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01606007
  • EudraCT 2012-000679-18
Main results
  • Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin Diabetes care, 2015-03 DOI, PubMed 25352655
Other papers using this trial's data
  • Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin Archives of endocrinology and metabolism, 2018-08 DOI, PubMed 30304106, PMC10118728 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada, Mexico, Poland, Puerto Rico, Romania, South Africa, South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01606007. Randomized; triple masking; primary purpose treatment. Start 2012-07 (registry gives no type); primary completion 2014-01 (actual). Results posted on 2015-10-20.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes
Intervention (Drug)
Saxagliptin
Intervention (Drug)
Metformin XR
Intervention (Drug)
Dapagliflozin
Intervention (Drug)
Placebo matching with Dapagliflozin
Intervention (Drug)
Placebo matching with Saxagliptin
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct01606007
Content hash
9627799ccaf9ff0eee33f84e4ec73473d1633032a979bf878e4f07a1d071fc2e